GLP-3 miligaramu 10

▎ GLP-3 sigicogo

▎ GLP-3 Sɛgɛsɛgɛli

GLP-3 ka ɲininiw kɛcogo ye mun ye?

Fasa ye foroba kɛnɛyako gɛlɛyabaw dɔ ye bi. Fasa bɛ se ka kɛ sababu ye ka kɛnɛya gɛlɛya suguya caman sɔrɔ, i n’a fɔ farikoloɲɛnajɛ suguya 2, dusukunnabana, tansiyɔn jiginni, jolidɛsɛ, ani sugunɛbilenni min tɛ dɔlɔ ye. Ni fasa hakɛ bɛ ka caya ka taa a fɛ, furakɛli kura ɲinini bɛ ka caya minnu bɛ se ka farikolo girinya kunbɛn ka ɲɛ ani ka kɛnɛya sabati ^[1] . Hali ni ɲɛnamaya kɛcogo caman caman cili, i n’a fɔ farikoloɲɛnajɛ caya ani dumuni dunta dɔgɔyali, olu de ye farikolo girinya kunbɛncogo fɔlɔw ye, farikolo girinya dɔgɔyali kuntaalajan marali bɛ to gɛlɛya ye baliku caman bolo minnu bananen don. GLP-3 ye agoniste sabatilen kura ye min bɛ baara kɛ glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), ani glucagon receptor (GCGR) kan. O baarakɛcogo min bɛ kɛ ni jaabi caman ye, o bɛ nafa kɛrɛnkɛrɛnnenw di a ma farikolo girinya dɔgɔyali la. Ni aw ye a suma ni farikolojidɛsɛ furaw ye minnu bɛ baara kɛ furakisɛ kelen kan, GLP-3 bɛ se ka farikolo ka farikoloɲɛnajɛ kɛcogo ɲɛnabɔ ka ɲɛ ^[1] . GLP-3 bɛ mɔgɔ farikolo girinya dɔgɔya ni a bɛ ɔrimɔni caman minɛcogo ɲɛnabɔ. A tɛ kɛ dɔrɔn ka mɔgɔ farikolo girinya dɔgɔya, nka a bɛ kɔnɔboli jugumanba fana sɔrɔ. Ka fara o kan, ni i ye a suma ni farikolojidɛsɛ fura kura wɛrɛw ye, GLP-3, i n’a fɔ a bɛ se ka kɛ sababu ye ka mɔgɔ saba minɛ, o bɛ farikolojidɛsɛ fanga bonya ani ka jamanaden caman sɔrɔ minnu bɛ se ka kɛ.

GLP-3 ka baarakɛcogo ye mun ye?

GLP-3 ka baarakɛcogo bɛ bɔ a ka agoniste nɔw de la kosɛbɛ a minɛbaga caman kan. A fɔlɔ, a ka agoniste nɔ min bɛ glucagon-like peptide-1 receptor (GLP-1R) la, o bɛ dɔ fara insuline bɔli kan, ka glucagon bɔli bali, ka joli sukaro hakɛ dɔgɔya, ani o waati kelen na, a bɛ kɔnɔbara lankolonya bila kɔfɛ, ka dɔ fara fasa kan, ka dumuni ^dunta dɔgɔya Filanan, a ka agoniste nɔ min bɛ inisɔndiyalan polipɛtidi minɛbaga (GIPR) la min bɛ tali kɛ sukaro la, o bɛ se ka inisɔndiya bɔli sabati, ka sukaro baara caya, ani ka nɔ bila tulumafɛnw falenni na, ka tulumafɛnw bɔli bali ani ka tulumafɛnw ^sɔrɔli sabati Ka fara o kan, hali ni GLP-3 ka agoniste nɔ min bɛ glucagon minɛbaga (GCGR) kan, a ka c’a la, o bɛ glycogenolyse ni gluconeogenesis sabati sugunɛ na, ka dɔ fara joli sukaro hakɛ kan, GLP-3 ka baara kɔnɔ, o nɔ min bɛ joli sukaro cayalenba la, o bɛ ban ni glycogenolyse ni gluconeogenesis ye. O waati kelen na, a bɛ tulumafɛnw bɔli sabati ani ka tulumafɛnw dalajɛli dɔgɔya ^[2] . Nin wale kɛcogo min bɛ kɛ ni laɲini caman ye, o bɛ se ka kɛ sababu ye ka fasa furakɛ ka tɛmɛ farikolojidɛsɛ fura kelenw kan.

Ni GLP-3 ye nin farikolojɔlan saba ninnu baara waati kelen na, a bɛ se ka farikoloɲɛnajɛ kɛcogo caman kɛ ani ka furakɛli nɔw lase fasa ni banaw ma minnu bɛ tali kɛ o la. Joli sukaro hakɛ labɛnni siratigɛ la, ka da GLP-1R ni GIPR baarakɛli kan min bɛ inisɔndiya bɔli sabati ani ka sukaro bɔli bali, ani GCGR baarakɛli min bɛ kunbɛn ni a minɛbaga fila tɔw nɔ ye, GLP-3 bɛ se ka joli sukaro hakɛ labɛn ka ɲɛ, o min nafa ka bon kosɛbɛ farikoloɲɛnajɛ suguya 2 furakɛli la ^{[1, 2} ] Tumu dalajɛli dɔgɔyali siratigɛ la, GCGR baarakɛli bɛ tulumafɛnw bɔli sabati ani ka tulumafɛnw dalajɛli dɔgɔya. O waati kelen na, GLP-1R baarakɛli bɛ dɔ fara fasa kan ani ka dumuni dunta dɔgɔya, o bɛ dɔ bɔ tulumafɛnw sɔrɔli la ka taa a fɛ ^{[1, 2]} . Ka fara o kan, GLP-3 fana bɛ nɔ ɲuman bila sugunɛbilenni na min tɛ dɔlɔ ye. A bɛ se ka tulu hakɛ dɔgɔya sugunɛ na ani ka sugunɛ baara ɲɛ. Kɔrɔbɔli min kɛra ni mɔgɔw ye, min kɛra ni mɔgɔ fila ye, min kɛra ni furakisɛ ye, o y’a jira ko sugunɛ tulu caman yeli ɲɔgɔn fɛ GLP-3 furakɛli kulu la dɔgɔkun 24 kɔnɔ, o tun ka dɔgɔn kosɛbɛ ka tɛmɛ furakisɛ ta kulu ta ^kan.

HbA1c, farikolo girinya, tansiyɔn, ani tulumafɛnw Kunnafoni ye fɛnw ye minnu ka dɔgɔn (ni filiw bɛ SEw jira) ka bɔ nafa sɛgɛsɛgɛli kulu la, fo ni a fɔra cogo wɛrɛ la.

Soso:PubMed ^{[4] Ɲɛjirali dɔw.}

GLP-3 bɛ sukaro sɛnɛcogo ɲɛnabɔ cogo di tigitigi, a kɛlen kɔ ka a minɛbaga saba baara?

GLP-3 bɛ joli sukaro labɛn fɛɛrɛ caman fɛ, i n’a fɔ GLP-1 ni GIP minɛbagaw baara, ka inisɔndiya bɔli lawuli, ka sukaro bɔli bali, ka kɔnɔbara lankolonya bila kɔfɛ, ka tulumafɛnw sɛnɛcogo ɲɛnabɔ, ani ka ANGPTL3/8 hakɛ dɔgɔya. Joli sukaro labɛnni siratigɛ la, GLP-3 bɛ baara kɛ GLP-1 ni GIP minɛbagaw kan, ka pankreyasi β selilɛriw ka se ka sukaro sɔrɔ, ka inisɔndiya sɔrɔ ani ka a bɔ, ka sɔrɔ ka sukaro tali ni a baara sabati farikolo yɔrɔw fɛ, ka se ka joli sukaro dɔgɔyali nɔ sɔrɔ ^{[4, 5]} .Ka sɛgɛsɛgɛli dɔ kɛ farikoloɲɛnajɛ suguya 2 banabagatɔw kan, GLP-3 ye nɔba jira ka ɲɛsin ɛmoɲini glycété (HbA1c) dɔgɔyali ma, o min bɛ nafa caman sɔrɔ a jɔyɔrɔ la inisɔndiya bɔli la (Rosenstock J, 2023). O waati kelen na, GLP-1 minɛbaga baara bɛ se ka sukaro bɔli bali pankreyasi α selilɛriw fɛ, ka joli sukaro bali ka caya kojugu. Dɔgɔtɔrɔso ka sɛgɛsɛgɛliw la, a kɔlɔsira ko banabagatɔ minnu bɛ GLP-3 ta, olu ka sukaro hakɛ dɔgɔyara, o min bɛ dɛmɛ ka joli sukaro sabatili sabati ^{[4, 5]} . GLP-1 ni GIP minɛbagaw baarakɛli fana bɛ se ka kɔnɔbara lankolonya hakɛ bila kɔfɛ, ka dumuni toli ni a minɛni sumaya, ani ka dɔ bɔ dumuni kɔfɛ joli sukaro jiginni jugumanba la. Kɔlɔsiliw y’a jira ko banabagatɔ minnu furakɛra ni GLP-3 ye, olu kɔnɔbara lankolonya waati bɛ janya kosɛbɛ dumuni kɛlen kɔfɛ, o bɛ dɔ bɔ dumuni kɔfɛ sukaro hakɛ dantɛmɛnen ^na.

GLP-3 ka tulumafɛnw sɛnɛcogo ɲɛnabɔli fana bɛ nɔ bila sukaro sɛnɛcogo la cogo la min tɛ ɲɛ. Misali la, banabagatɔ fasalenw ka sɛgɛsɛgɛliw la, a jirala ko GLP-3 bɛ se ka kolosinsinnanw hakɛ dɔgɔya triglycérides (TG), lipoprotéines low-density (LDL), ani lipoprotéines low-density (VLDL) hakɛ la ^[2 , Nin ɲɛtaa in min bɛ kɛ tulumafɛnw falenni na, o bɛ se ka kɛ sababu ye ka inisɔndiya kɛcogo ɲɛ, o la, o bɛ kɛ sababu ye ka joli sukaro hakɛ kunbɛn. Kɛrɛnkɛrɛnnenya la, GLP-3 furakɛli kɔfɛ, asidi 3-hidroksibutiririki (3-HB) bɛ bonya joli la, o bɛ taa ni 3-hidroksibutirilikarnitini (C ₄OH) caya ye, asetilkarnitini ni karɔnitini hɔrɔnma hakɛ (C ₂/C ₀), ani asilikarinitini cakɛda cɛmancɛ la, o b’a jira ko tulumafɛnw ka lipolisi bɛ bonya ani ka dɔ fara tulumafɛnw kan oksidan sɔrɔli.

GLP-3 bɛ se ka dihidroseramidi (DhCers) bɛɛ lajɛlen fana dɔgɔya, wa o fɛn caman Changement bɛ tali kɛ inisɔndiya sɔrɔli la, sugunɛbilenni dɔgɔyali, ani farikolo funu ^[6] waati kelen na, GLP-3 bɛ se ka ANGPTL3/8 complexe hakɛ dɔgɔya fana farikoloɲɛnajɛ suguya 2 banabagatɔw ka joli la, ka sukaro sɛnɛcogo ^ɲɛnabɔ .O ANGPTL3/8 ye lipoprotéine lipase (LPL) balilan ye min bɛ se ka farikolo lamini, wa a joli la hakɛ bɛ tali kɛ TG ni lipoprotéine cholesterol low-density (LDL-C) la. GLP-3 bɛ ANGPTL3/8 hakɛ dɔgɔya, o min bɛ se ka sukaro sɛnɛcogo ɲɛnabɔ ni a bɛ lipoprotéines triglycérides caman dɔgɔya ^{[7] .} .

GLP-3 b’a nɔw jira fan jumɛnw na?

Kisɛya dɔgɔyali nɔba min bɛ mɔgɔ la: 

GLP-3 ye farikolo girinya dɔgɔyali nɔba jira kɛnɛyaso sɛgɛsɛgɛli caman na. Misali la, kɛnɛyaso ka sɛgɛsɛgɛli dɔ la min kɛra baliku 338 kan ^[2] , banabagatɔ minnu furakɛra ni GLP-3 hakɛ danfaralenw ye, olu girinya dɔgɔyara kosɛbɛ dɔgɔkun 48 kɔnɔ. Olu la, banabagatɔ minnu tun bɛ miligaramu 12 tata hakɛ kulu la, olu girinya dɔgɔyara ni 24,2% ye, wa banabagatɔ hakɛ caman ye girinya dɔgɔyali sɔrɔ hakɛ caman na. Misali la, banabagatɔ minnu ye miligaramu 4, miligaramu 8 ani miligaramu 12 ta, banabagatɔ 92%, 100% ani 100% ye u farikolo girinya dɔgɔya 5% walima ka tɛmɛ o kan. Kalan wɛrɛ la ^[8] , sɛgɛsɛgɛli fila minnu kɛra ni mɔgɔw ye minnu kɛra ni farikoloɲɛnajɛ suguya 2 banabagatɔ 353 ye, olu y’a jira ko ni i ye a suma ni furakisɛ ta ye, GLP-3 bɛ se ka banabagatɔw farikolo girinya dɔgɔya kosɛbɛ ni kilogaramu 11,89 ye ani ka ɛmoɲini glycété (HbA1C) dɔgɔya. Ka fara o kan, banabagatɔ fasalen minnu tɛ sukarodunbana ye, olu ka kɔrɔbɔli dɔ la, GLP-3 kɛra sababu ye ka banabagatɔw girinya dɔgɔya ni 24,2% ye, ani banabagatɔ 83% ye u farikolo girinya dɔgɔya 15% walima ka tɛmɛ o kan dɔgɔkun 48 kɔnɔ. Nin jaabi ninnu b’a jira ko GLP-3 bɛ se ka mɔgɔ farikolo girinya dɔgɔya.

Farikoloɲɛnajɛ suguya 2 furakɛli : . 

GLP-3 fana bɛ seko dɔw jira farikoloɲɛnajɛ suguya 2 furakɛli la. Kɛnɛyaso sɛgɛsɛgɛli dɔw la, GLP-3 y’a jira ko dɔ bɔra ɛmoɲini glycété (HbA1c) la ani ka girinya dɔgɔya min bɛ bɔ a tata hakɛ la. Misali la, sɛgɛsɛgɛli dɔ la, farikolojidɛsɛ suguya 2 banabagatɔw la, GLP-3 ye joli sukaro kɔlɔsili nɔba jira, ka joli sukaro hakɛ dɔgɔya ni 1,64% ye ni i ye a suma ni furakisɛ ta ye ^[4 , Ka fara o kan, sɛgɛsɛgɛli dɔ la min kɛra ni mɔgɔw ye, ni fiyentɔ fila ye, furakisɛ fila ye, ani kulu kelen-kelen bɛɛ ka fasa 2 sɛgɛsɛgɛli la, baganw ka misali minnu bɛ ni farikoloɲɛnajɛ suguya 2 ye, olu y’a jira ko dɔ bɔra kosɛbɛ ɛmoɲini hakɛ la min bɛ kɛ ni sukaro ye ani ka girinya dɔgɔyali min bɛ bɔ a tata hakɛ la, GLP-3 ^kɔfɛ furakɛli O bɛ se ka kɛ fura in nɔ bɛɛ lajɛlen ye GLP-1, GCGR ani GIPR la, olu minnu bɛ sukaro sɛnɛcogo ni fanga balansi ɲɛ.

Dusukun ni jolisiraw ka faratiw ɲɛnabɔli: 

GLP-3 tɛ se ka farikolo girinya dɔgɔya dɔrɔn, nka a bɛ se ka dusukun ni jolisiraw ka faratiw fana ɲɛ, i n’a fɔ joli segin furakisɛw hakɛ ani joli segin furakisɛw hakɛ. O b’a jira ko jɛɲɔgɔnya gɛlɛn bɛ fasa ni dusukunnabana cɛ, wa GLP-3 bɛ se ka fasa banabagatɔw dusukun ni jolisiraw kɛnɛya sabati sira caman fɛ. Misali la, ni aw ye dɔ bɔ u hakɛ la minnu tɛ HDL-C, apoB ani LDLP ye, o bɛ se ka dɔ bɔ joli siraw la; ni jolisegindumuniw hakɛ dɔgɔyali bɛ se ka joli sukaro hakɛ kunbɛnni ɲɛ farikolojɔli banabagatɔw la, o bɛ dusukun ni jolisiraw gɛlɛyaw dɔgɔya ^{[8-10] .} .

Sugunɛbilenni min tɛ dɔlɔ ye (NAFLD) furakɛli : 

GLP-3 ye pepitiri sabatilen agoniste kura ye min bɛ glucagon minɛbaga (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) ani glucagon-like peptide-1 receptor (GLP-1R) laɲini. Kɔlɔsiliw y’a jira ko GLP-3 bɛ se ka sugunɛbilenni furakɛ min tɛ dɔlɔ ye. Kalan dɔ la, sɛgɛsɛgɛli min kɛra ni mɔgɔw ye, min kɛra ni mɔgɔ fila ye, min kɛra ni furakisɛ ye, min kɛra dɔgɔkun 48 kɔnɔ, o kɛra mɔgɔ minnu kan, minnu ka sugunɛbilenni bɛ sɔrɔ farikoloɲɛnajɛ baarakɛbaliya fɛ, ani sugunɛ tulu hakɛ ye ≥10% ye. Jateminɛw y’a jira ko dɔgɔkun 24 kɔnɔ, sugunɛ tulu caman yeli ni a daminɛ na, mɔgɔ minnu furakɛra ni GLP-3 hakɛ danfaralenw ye (miligaramu 1, miligaramu 4, miligaramu 8, ani miligaramu 12) olu kɛra -42,9%, -57,0%, -81,4% ani -82,4% ye, k’a sɔrɔ furakisɛ kulu ta kɛra +0,3 ^% ye O b’a jira ko GLP-3 bɛ se ka furakɛli nɔba bila sugunɛbilenni na min tɛ dɔlɔ ye.

Kuncɛli la, i n’a fɔ agoniste triple receptor kura, GLP-3 bɛ sebaayaba jira fasa ni bana minnu bɛ tali kɛ a la. A bɛ se ka sukaro minɛbaga, insulinotropi polipɛtidi minɛbaga min bɛ tali kɛ sukaro la, ani pepitiri-1 minɛbaga min bɛ tali kɛ sukaro la, o baara, ka farikolo ka farikoloɲɛnajɛ labɛn ka ɲɛ ka bɔ yɔrɔ caman na, ka joli sukaro kunbɛnni ɲɛ, ka farikolo girinya dɔgɔya, ani ka tulumafɛnw sɛnɛcogo ɲɛnabɔ. GLP-3 bɔli bɛ na ni furakɛli suguya kuraw ye banabagatɔw ma minnu fasalen don, farikoloɲɛnajɛ suguya 2 bɛ minnu na, ani bana wɛrɛw. A jirala ko a bɛna dancɛw tigɛ laadala furaw la minnu bɛ mɔgɔ kelen-kelen agoniste furakɛ, ka kɛ marifa barikama ye walasa ka fasa ni farikoloɲɛnajɛ banaw gɛlɛyabaw ɲɛnabɔ minnu bɛ ka caya ka taa a fɛ, ka furakɛli yɔrɔw yiriwa ka taa a fɛ, minnu bɛ tali kɛ ɲɔgɔn na, ka banabagatɔw ka ɲɛnamaya kɛcogo ɲɛ, ani ka dɔ bɔ sigida furakɛli doni na.

A sɛbɛnbaga ko la

Fɛn minnu kofɔlen dòn san fɛ, olu bɛɛ ɲinini Kɛra, k’u Labɛn ani k’u Lajɛ Cocer Peptides fɛ.

Dɔnniya gafe sɛbɛnbaga

Rosenstock J ye dɔnnikɛla ye min fanga ka bon kosɛbɛ furakɛli siratigɛ la, a ni baaradaw bɛ baara kɛ ɲɔgɔn fɛ kosɛbɛ i n’a fɔ Texas Iniwɛrisite Saheli-Tilebin-yanfan dɔgɔtɔrɔso ani Texas Iniwɛrisite Dallas. A bɛ ɲininiw kɛ fana santiriw la i n’a fɔ Kanada VIGOR Center ani Veloc Clin Res Ctr Med City. A ka ɲininiw bɛ tali kɛ kɔnɔnatumuw ni farikoloɲɛnajɛw la, dusukun ni jolisiraw ni dusukunnakow la, furakɛlicogo la, ani furakɛli kɛcogo kɔrɔbɔli la, k’a sinsin farikoloɲɛnajɛ, fasa, ani furakɛli minnu bɛ tali kɛ o la ani furaw dilanni kan. J Rosenstock ye ɲɛtaa caman sɔrɔ kɛnɛyaso furakɛli la, a tɔgɔ dara ko ɲininikɛla min tɔgɔ bɔra kosɛbɛ k’a ta san 2017 la ka se san 2024. O b’a jira ko a ka baara ye nɔba bila a la ani ko a dɔnna kosɛbɛ. A ni ɲininikɛla caman ka jɛkafɔ sababu fɛ, a ye ɲinini jɔnjɔnw sɔrɔlenw baara ka ɲɛ ka kɛ kɛnɛyaso baarakɛcogo ye, ka farikoloɲɛnajɛ ni dusukunnabana banabagatɔw nafa ani ka furakɛli dɔnniya yiriwa. Rosenstock J tɔgɔ sɛbɛnnen bɛ citation (citation) ɲɛfɔli sɛbɛn kɔnɔ [4].

▎ Sɛbɛn minnu bɛ tali kɛ o la

[1] Kaur M, Misra S. Sɛgɛsɛgɛli fura dɔ seginnkanni GLP-3, o ye agoniste saba fura kura ye fasa furakɛli kama[J]. Erɔpu jamanaw ka furakɛli gafe, 2024,80(5):669-676.DOI:10.1007/s00228-024-03646-0.

[2] Jastreboff A. M., Kaplan L. M., Frias J. P., ani a ɲɔgɔnnaw. Triple-Hormone-Receptor Agonist GLP-3 ka ɲɛsin fasa-A fasa 2 sɛgɛsɛgɛli ma[J]. Angletɛri kura ka furakɛli gafe, 2023,389(6):514-526.DOI:10.1056/NEJMoa2301972.

[3] Sanyal A. J., Kaplan L. M., Frias J. P., ani mɔgɔ wɛrɛw. Hormone récepteur saba GLP-3 ka ɲɛsin farikolojɔli baarakɛbaliya ma sugunɛbana fɛ: a kɛra sɛgɛsɛgɛli kɛcogo la min kɛra fasa 2a kɔnɔ[J]. Sigida furakɛli, 2024,30(7):2037-2048.DOI:10.1038/s41591-024-03018-2.

[4] Rosenstock J, Frias J, Jastreboff A. M., ani mɔgɔ wɛrɛw. GLP-3, n’o ye GIP, GLP-1 ani glucagon receptor agoniste ye, farikoloɲɛnajɛ suguya 2 bɛ mɔgɔ minnu na: sɛgɛsɛgɛli min kɛra k’a sɔrɔ a ma kɛ cogo si la, min kɛra ni fiyentɔ fila ye, min kɛra furakisɛ ye ani min bɛ kɛ ni wale ye, min bɛ kɛ ni kulu ye min bɛ taa ɲɔgɔn fɛ, fasa 2nan na, min kɛra USA[J Lancet, 2023,402(10401):529-544.DOI:10.1016/S0140-6736(23)01053-X. Bamako, Mali.

[5] Brzozowska P, Frańczuk A, Nowinska B, ani a ɲɔgɔnnaw. GLP-3 - revolutionary kɔsa in na GLP agoniste - sɛbɛnw lajɛ[J]. Jogo ɲuman farikoloɲɛnajɛ la, 2024.DOI:10.12775/qs.2024.15.52125.

[6] Pirro V, Pearson M. J., Lin Y, ani mɔgɔ wɛrɛw. Triple-Hormone Receptor Agonist GLP-3 nɔ minnu bɛ lipid Profiling la fasa bɛ mɔgɔ minnu na[J]. Jabɛtibana, 2024,73.DOI:10.2337/db24-117-OR.

[7] Wen Y, Lemen D, Chen Y, ani a ɲɔgɔnnaw. Triglycérides nafama lipoprotéines ni GLP-3 dɔgɔyali farikoloɲɛnajɛ suguya 2 la, o bɛ se ka ɲɛfɔ ni ANGPTL3/8 hakɛ dɔgɔyali ye waati kelen na[J]. Erɔpu dusukunnakow gafe, 2024,45.DOI:10.1093/eurheartj/ehae666.2862.

[8] Lopez D. C., Pajimna J. T., Milan M. D., ani a ɲɔgɔnnaw. 7792 GLP-3 nafa ka bon farikolo girinya dɔgɔyali la ani a dusukun ni farikoloɲɛnajɛ nɔw balikuw la: Seginkanni sigilen ni a sɛgɛsɛgɛli[J]. Ɲɛnamaya kɛcogo ɲuman ka gafe, 2024,8(1):163-749.DOI:10.1210/jendso/bvae163.749.

[9] Nicholls S, Pirro V, Lin Y, ani a ɲɔgɔnnaw. Triple-hormone receptor agonist GLP-3 bɛ lipoprotéines ni apolipoprotéines cogoya ɲɛ kosɛbɛ mɔgɔ minnu ka fasa walima minnu girinya ka ca[J]. Erɔpu dusukunnakow gafe, 2024,45.DOI:10.1093/eurheartj/ehae666.1501.

[10] Ray A. GLP-3: inkretini minɛbaga saba ye fasa kunbɛnni na[J]. Sɛgɛsɛgɛli furaw kan dɔnnikɛlaw ka hakilina, 2023,32(11):1003-1008.DOI:10.1080/13543784.2023.2276754.

BƐƐRƐ KUNNAFONIW NI FƐRƐW KUNNAFONIW BƐƐ MIN BƐ NI WEBSITE KAN NA, U BƐ KUNNAFONIW FƆLƆ DƆRƆN NI KALANSENW YE.  

Fɛn minnu bɛ di nin siti in kan, olu dabɔra ɲininiw dɔrɔn kama in vitro. Sɛgɛsɛgɛli in vitro (latinkan na: *in glass*, o kɔrɔ ye gilasi minɛnw na) bɛ kɛ hadamaden farikolo kɔkan. Nin fura ninnu tɛ furaw ye, Ameriki dumuniko ni furako ɲɛmɔgɔso (FDA) ma sɔn u ma, wa u man kan ka kɛ ka furakɛli bana, bana walima bana si bali, k’a furakɛ, walima k’a furakɛ. A dagalen don kosɛbɛ sariya fɛ ka nin fɛn ninnu don hadamaden walima bagan farikolo la cogo o cogo.